LT3630112T - Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui - Google Patents
Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymuiInfo
- Publication number
- LT3630112T LT3630112T LTEPPCT/EP2018/063785T LTEP2018063785T LT3630112T LT 3630112 T LT3630112 T LT 3630112T LT EP2018063785 T LTEP2018063785 T LT EP2018063785T LT 3630112 T LT3630112 T LT 3630112T
- Authority
- LT
- Lithuania
- Prior art keywords
- regorafenib
- nivolumab
- cancer
- treatment
- combination
- Prior art date
Links
- 239000002138 L01XE21 - Regorafenib Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960003301 nivolumab Drugs 0.000 title 1
- 229960004836 regorafenib Drugs 0.000 title 1
- ZOPOQLDXFHBOIH-UHFFFAOYSA-N regorafenib hydrate Chemical compound O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 ZOPOQLDXFHBOIH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174169 | 2017-06-02 | ||
| PCT/EP2018/063785 WO2018219807A1 (en) | 2017-06-02 | 2018-05-25 | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3630112T true LT3630112T (lt) | 2024-05-10 |
Family
ID=58992733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2018/063785T LT3630112T (lt) | 2017-06-02 | 2018-05-25 | Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11951166B2 (enExample) |
| EP (2) | EP4342542A3 (enExample) |
| JP (3) | JP7303122B2 (enExample) |
| KR (2) | KR102843438B1 (enExample) |
| CN (3) | CN117899212A (enExample) |
| AU (2) | AU2018276273B2 (enExample) |
| BR (1) | BR112019025478A8 (enExample) |
| CA (2) | CA3244313A1 (enExample) |
| DK (1) | DK3630112T3 (enExample) |
| ES (1) | ES2978337T3 (enExample) |
| FI (1) | FI3630112T3 (enExample) |
| HR (1) | HRP20240551T1 (enExample) |
| HU (1) | HUE066487T2 (enExample) |
| IL (2) | IL270948B2 (enExample) |
| LT (1) | LT3630112T (enExample) |
| MX (1) | MX2023001721A (enExample) |
| PE (2) | PE20242220A1 (enExample) |
| PL (1) | PL3630112T3 (enExample) |
| PT (1) | PT3630112T (enExample) |
| RS (1) | RS65488B9 (enExample) |
| SI (1) | SI3630112T1 (enExample) |
| WO (1) | WO2018219807A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018276273B2 (en) | 2017-06-02 | 2023-12-21 | Bayer Healthcare Llc | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer |
| CN111001004A (zh) * | 2019-10-08 | 2020-04-14 | 广州医科大学附属第二医院 | 一种治疗肝癌的药物组合及其应用 |
| WO2025117638A1 (en) * | 2023-12-01 | 2025-06-05 | Yale University | Compositions and methods for treating cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| WO2007054303A2 (en) | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl urea for treating diabetic neuropathy |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| AR092439A1 (es) * | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
| MX357035B (es) * | 2012-09-25 | 2018-06-25 | Bayer Pharma AG | Combinacion de regorafenib y acido acetilsalicilico para el tratamiento del cancer. |
| JP5653489B1 (ja) | 2013-07-24 | 2015-01-14 | 三菱エンジニアリングプラスチックス株式会社 | 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法 |
| EP3102605B1 (en) | 2014-02-04 | 2018-11-14 | Pfizer Inc | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
| US20170165364A1 (en) | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| CA2954508A1 (en) * | 2014-07-15 | 2016-01-21 | Genentech, Inc. | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| AU2015289922A1 (en) | 2014-07-15 | 2017-02-16 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| JP6698084B2 (ja) * | 2014-08-08 | 2020-05-27 | オンコクエスト インコーポレイテッドＯｎｃｏｑｕｅｓｔ Ｉｎｃ． | がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびｔｌｒ３刺激 |
| KR20170042778A (ko) * | 2014-08-19 | 2017-04-19 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법 |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| KR20170080697A (ko) | 2014-11-13 | 2017-07-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| WO2016173959A1 (en) * | 2015-04-28 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Regorafenib for treating colorectal cancer |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| JP2019517507A (ja) | 2016-06-03 | 2019-06-24 | イムクローン リミテッド ライアビリティ カンパニー | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| AU2018276273B2 (en) | 2017-06-02 | 2023-12-21 | Bayer Healthcare Llc | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer |
| WO2018226580A2 (en) * | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that specifically bind pd-1 and methods of use |
-
2018
- 2018-05-25 AU AU2018276273A patent/AU2018276273B2/en active Active
- 2018-05-25 HU HUE18725258A patent/HUE066487T2/hu unknown
- 2018-05-25 JP JP2019565949A patent/JP7303122B2/ja active Active
- 2018-05-25 IL IL270948A patent/IL270948B2/en unknown
- 2018-05-25 SI SI201831091T patent/SI3630112T1/sl unknown
- 2018-05-25 CA CA3244313A patent/CA3244313A1/en active Pending
- 2018-05-25 FI FIEP18725258.0T patent/FI3630112T3/fi active
- 2018-05-25 WO PCT/EP2018/063785 patent/WO2018219807A1/en not_active Ceased
- 2018-05-25 PT PT187252580T patent/PT3630112T/pt unknown
- 2018-05-25 PL PL18725258.0T patent/PL3630112T3/pl unknown
- 2018-05-25 HR HRP20240551TT patent/HRP20240551T1/hr unknown
- 2018-05-25 US US16/617,642 patent/US11951166B2/en active Active
- 2018-05-25 BR BR112019025478A patent/BR112019025478A8/pt not_active Application Discontinuation
- 2018-05-25 CA CA3065125A patent/CA3065125C/en active Active
- 2018-05-25 CN CN202410088226.5A patent/CN117899212A/zh active Pending
- 2018-05-25 IL IL317015A patent/IL317015A/en unknown
- 2018-05-25 EP EP24150061.0A patent/EP4342542A3/en active Pending
- 2018-05-25 DK DK18725258.0T patent/DK3630112T3/da active
- 2018-05-25 RS RS20240481A patent/RS65488B9/sr unknown
- 2018-05-25 CN CN201880036504.5A patent/CN110662540B/zh active Active
- 2018-05-25 KR KR1020247017968A patent/KR102843438B1/ko active Active
- 2018-05-25 PE PE2024001939A patent/PE20242220A1/es unknown
- 2018-05-25 KR KR1020197038281A patent/KR102673422B1/ko active Active
- 2018-05-25 CN CN202311446796.9A patent/CN117582495A/zh active Pending
- 2018-05-25 EP EP18725258.0A patent/EP3630112B9/en active Active
- 2018-05-25 ES ES18725258T patent/ES2978337T3/es active Active
- 2018-05-25 LT LTEPPCT/EP2018/063785T patent/LT3630112T/lt unknown
- 2018-05-25 PE PE2019002499A patent/PE20200859A1/es unknown
-
2019
- 2019-12-02 MX MX2023001721A patent/MX2023001721A/es unknown
- 2019-12-31 US US16/731,412 patent/US11517622B2/en active Active
- 2019-12-31 US US16/731,409 patent/US20200155674A1/en not_active Abandoned
-
2022
- 2022-01-14 US US17/576,522 patent/US20220133888A1/en active Pending
- 2022-09-01 JP JP2022138972A patent/JP7475402B2/ja active Active
-
2023
- 2023-12-12 AU AU2023282197A patent/AU2023282197B2/en active Active
-
2024
- 2024-04-16 JP JP2024066115A patent/JP2024096905A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269150A (en) | Compositions and methods for treating cancer | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| IL270511A (en) | Combination therapies using niraparib and pembrolizumab for treating cancer | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL268814A (en) | Compositions and methods for treatment of cancer | |
| IL258955A (en) | Compositions and methods for treatment of cancer | |
| IL263224A (en) | Methods and compositions for treating cancers | |
| EP3601536A4 (en) | TREATMENT PROCESSES | |
| LT3283527T (lt) | Kompleksinė terapija vėžio gydymui | |
| IL267795A (en) | Combined treatment for cancer | |
| LT3416957T (lt) | 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui | |
| LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
| IL269157A (en) | Compositions and methods for treating cancer | |
| IL268463A (en) | Cancer treatment | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| LT3496743T (lt) | Kompozicijos ir metodai, skirti vėžio gydymui arginino deplecija ir imunoonkologiniais preparatais | |
| HUE053648T2 (hu) | Gyógyászati kombinációk rák kezelésére | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| EP3597225A4 (en) | TREATMENT PROCESS | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| LT3630112T (lt) | Regorafenibo ir nivolumabo derinys, skirtas vėžio gydymui | |
| EP3578162A4 (en) | HAIR TREATMENT METHOD | |
| LT3352857T (lt) | T-dm1 atsparių, vėžiu sergančių pacientų gydymas junginiu syd985 | |
| EP3582781A4 (en) | A method of treatment |